BerandaLONA • NASDAQ
add
LeonaBio Inc
Tutup sebelumnya
$10,02
Rentang hari
$9,51 - $11,71
Rentang tahun
$4,22 - $14,19
Kapitalisasi pasar
106,62 jt USD
Volume Rata-Rata
79,43 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 78,56 jt | 404,72% |
Penghasilan bersih | -82,89 jt | -452,48% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -78,32 jt | -411,14% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 88,33 jt | 72,27% |
Total aset | 92,15 jt | 56,78% |
Total liabilitas | 64,36 jt | 361,77% |
Total ekuitas | 27,79 jt | — |
Saham yang beredar | 5,35 jt | — |
Harga terhadap nilai buku | 1,93 | — |
Tingkat pengembalian aset | -321,50% | — |
Tingkat pengembalian modal | -686,40% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -82,89 jt | -452,48% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
19
